Critical Reviews in Oncology / Hematology
Volume 74, Issue 2 , Pages 106-133, May 2010

Colon cancer

  • Roberto Labianca

      Affiliations

    • Ospedali Riuniti, Largo Barozzi 1, 24128 Bergamo, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 035 269860.
    • ,
  • Giordano D. Beretta

      Affiliations

    • Ospedale Sant’Orsola Fatebenefratelli, Brescia, Italy
    • ,
  • Basem Kildani

      Affiliations

    • Ospedale Sant’Orsola Fatebenefratelli, Brescia, Italy
    • ,
  • Laura Milesi

      Affiliations

    • Ospedali Riuniti, Largo Barozzi 1, 24128 Bergamo, Italy
    • ,
  • Federica Merlin

      Affiliations

    • Ospedale Sant’Orsola Fatebenefratelli, Brescia, Italy
    • ,
  • Stefania Mosconi

      Affiliations

    • Ospedali Riuniti, Largo Barozzi 1, 24128 Bergamo, Italy
    • ,
  • M. Adelaide Pessi

      Affiliations

    • Ospedali Riuniti, Largo Barozzi 1, 24128 Bergamo, Italy
    • ,
  • Tiziana Prochilo

      Affiliations

    • Ospedale Sant’Orsola Fatebenefratelli, Brescia, Italy
    • ,
  • Antonello Quadri

      Affiliations

    • Ospedali Riuniti, Largo Barozzi 1, 24128 Bergamo, Italy
    • ,
  • Gemma Gatta

      Affiliations

    • Fondazione IRCCS “Istituto Nazionale dei Tumori”, Milan, Italy
    • ,
  • Filippo de Braud

      Affiliations

    • START Project and European Institute of Oncology, Milan, Italy
    • ,
  • Jacques Wils

      Affiliations

    • Laurentius Hospital, Roermond, The Netherlands

Accepted 6 January 2010. published online 08 February 2010.

Abstract 

Colon cancer is one of the leading tumours in the world and it is considered among the big killers, together with lung, prostate and breast cancer. In the recent years very important advances occurred in the field of treatment of this frequent disease: adjuvant chemotherapy was demonstrated to be effective, chiefly in stage III patients, and surgery was optimized in order to achieve the best results with a low morbidity. Several new target-oriented drugs are under evaluation and some of them (cetuximab and bevacizumab) have already exhibited a good activity/efficacy, mainly in combination with chemotherapy. The development of updated recommendations for the best management of these patients is crucial in order to obtain the best results, not only in clinical research but also in every-day practice. This report summarizes the most important achievements in this field and provides the readers useful suggestions for their professional practice.

Keywords: Colon cancer, Strategy, Treatment

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1040-8428(10)00011-9

doi:10.1016/j.critrevonc.2010.01.010

Critical Reviews in Oncology / Hematology
Volume 74, Issue 2 , Pages 106-133, May 2010

Article Tools

* Image Usage & Resolution